Erratum for the research article: mTORC1 inhibition is required forsensitivity to PI3K p110a inhibitors in PIK3CA-mutant breast cancer (Science Translational Medicine DOI: 10.1126/scitranslmed.3005747);MTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer

Science Translational Medicine

Volumn 5, Issue 196, 2013, Pages

  Elkabets, Moshe ^a,b   Vora, Sadhna ^b   Juric, Dejan ^b   Morse, Natasha ^a   Mino Kenudson, Mari ^c   Muranen, Taru ^d   Tao, Jessica ^b   Campos, Ana Bosch ^a   Rodon, Jordi ^e   Ibrahim, Yasir H ^e   Serra, Violeta ^e   Rodrik Outmezguine, Vanessa ^a   Hazra, Saswati ^f   Singh, Sharat ^f   Kim, Phillip ^f   Quadt, Cornelia ^g   Liu, Manway ^h   Huang, Alan ^h   Rosen, Neal ^a   Engelman, Jeffrey A ^b   Scaltriti, Maurizio ^a   Baselga, José ^a   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^f Prometheus Therapeutics and Diagnostics   (United States)

^g NOVARTIS PHARMA AG   (Switzerland)

^h NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BYL 719; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; MOLECULAR MARKER; MTORC1 PROTEIN; NEU DIFFERENTIATION FACTOR; P110A PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B; PS6 PROTEIN; SOMATOMEDIN C; TORC1 PROTEIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ADULT; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CELL; CANCER RESISTANCE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; DRUG SENSITIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MULTIPLE CYCLE TREATMENT; NONHUMAN; PIK3CA GENE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ADULT; ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; INSULIN-LIKE GROWTH FACTOR I; MICE; MIDDLE AGED; MULTIPROTEIN COMPLEXES; MUTATION; NEUREGULIN-1; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; RIBOSOMAL PROTEIN S6; SIROLIMUS; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME;

EID: 84883624766     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aav9425     Document Type: Erratum

References (51)

1. J. A. Engelman, J. Luo, L. C. Cantley, The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet. 7, 606-619 (2006).
2. L. C. Cantley, The phosphoinositide 3-kinase pathway. Science 296, 1655-1657 (2002).
3. J. A. Engelman, Targeting PI3K signalling in cancer: Opportunities, challenges and limitations. Nat. Rev. Cancer 9, 550-562 (2009).
4. B. T. Hennessy, D. L. Smith, P. T. Ram, Y. Lu, G. B. Mills, Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat. Rev. Drug Discov. 4, 988-1004 (2005).
5. S. M. Brachmann, K. Ueki, J. A. Engelman, R. C. Kahn, L. C. Cantley, Phosphoinositide 3-kinase catalytic subunit deletion and regulatory subunit deletion have opposite effects on insulin sensitivity in mice. Mol. Cell. Biol. 25, 1596-1607 (2005).
6. L. Zhao, P. K. Vogt, Helical domain and kinase domain mutations in p110a of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc. Natl. Acad. Sci. U.S.A. 105, 2652-2657 (2008).
7. S. Kang, A. G. Bader, P. K. Vogt, Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc. Natl. Acad. Sci. U.S.A. 102, 802-807 (2005).
8. Y. Samuels, Z. Wang, A. Bardelli, N. Silliman, J. Ptak, S. Szabo, H. Yan, A. Gazdar, S. M. Powell, G. J. Riggins, J. K. Willson, S. Markowitz, K. W. Kinzler, B. Vogelstein, V. E. Velculescu, High frequency of mutations of the PIK3CA gene in human cancers. Science 304, 554 (2004).
9. T. W. Miller, B. N. Rexer, J. T. Garrett, C. L. Arteaga, Mutations in the phosphatidylinositol 3-kinase pathway: Role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res. 13, 224 (2011).
10. S. J. Isakoff, J. A. Engelman, H. Y. Irie, J. Luo, S. M. Brachmann, R. V. Pearline, L. C. Cantley, J. S. Brugge, Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res. 65, 10992-11000 (2005).
11. Q. B. She, S. Chandarlapaty, Q. Ye, J. Lobo, K. M. Haskell, K. R. Leander, D. DeFeo-Jones, H. E. Huber, N. Rosen, Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling. PLoS One 3, e3065 (2008).
12. S. M. Brachmann, I. Hofmann, C. Schnell, C. Fritsch, S. Wee, H. Lane, S. Wang, C. Garcia-Echeverria, S. M. Maira, Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells. Proc. Natl. Acad. Sci. U.S.A. 106, 22299-22304 (2009).
13. C. Gewinner, Z. C. Wang, A. Richardson, J. Teruya-Feldstein, D. Etemadmoghadam, D. Bowtell, J. Barretina, W. M. Lin, L. Rameh, L. Salmena, P. P. Pandolfi, L. C. Cantley, Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. Cancer Cell 16, 115-125 (2009).
14. H. Sun, R. Lesche, D. M. Li, J. Liliental, H. Zhang, J. Gao, N. Gavrilova, B. Mueller, X. Liu, H. Wu, PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway. Proc. Natl. Acad. Sci. U.S.A. 96, 6199-6204 (1999).
15. X. Wu, K. Senechal, M. S. Neshat, Y. E. Whang, C. L. Sawyers, The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc. Natl. Acad. Sci. U.S.A. 95, 15587-15591 (1998).
16. J. C. Bendell, J. Rodon, H. A. Burris, M. de Jonge, J. Verweij, D. Birle, D. Demanse, S. S. De Buck, Q. C. Ru, M. Peters, M. Goldbrunner, J. Baselga, Phase I, dose-escalation study of BKM120, an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. J. Clin. Oncol. 30, 282-290 (2012).
17. H. Burris, J. Rodon, S. Sharma, R. S. Herbst, J. Tabernero, J. R. Infante, A. Silva, D. Demanse, W. Hackl, J. Baselga, First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors. J. Clin. Oncol. 28, 3005 (2010).
18. D. D. Von Hoff, P. LoRusso, R. Tibes, G. Shapiro, G. J. Weiss, J. A. Ware, J. Fredrickson, K. E. Mazina, G. G. Levy, A. J. Wagner, A first-in-human phase I study to evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumors. J. Clin. Oncol. 28, 2541 (2010).
19. G. Shapiro, E. Kwak, J. Baselga, J. Rodon, C. Scheffold, A. D. Laird, C. Bedell, G. Edelman, Phase I dose-escalation study of XL147, a PI3K inhibitor administered orally to patients with solid tumors. J. Clin. Oncol. 27, 3500 (2009).
20. A. Huang, C. Fritsch, C. Wilson, A. Reddy, M. Liu, J. Lehar, C. Quadt, F. Hofmann, R. Schlegel, Single agent activity of PIK3CA inhibitor BYL719 in a broad cancer cell line panel. Cancer Res. 72 (2012).
21. D. Juric, G. Argiles, H. A. Burris, A. M. Gonzalez-Angulo, C. Saura, C. Quadt, M. Douglas, D. Demanse, S. De Buck, J. Baselga, Phase I study of BYL719, an alpha-specific PI3K inhibitor, in patients with PIK3CA mutant advanced solid tumors: Preliminary efficacy and safety in patients with PIK3CA mutant ER-positive (ER+) metastatic breast cancer (MBC). Cancer Res. 72 (2012).
22. D. Juric, J. Rodon, A. M. Gonzalez-Angulo, H. A. Burris, J. Bendell, J. D. Berlin, M. R. Middleton, D. Bootle, M. Boehm, A. Schmitt, N. Rouyrre, C. Quadt, J. Baselga, BYL719, a next generation PI3K alpha specific inhibitor: Preliminary safety, PK, and efficacy results from the first-in-human study. Cancer Res. 72 (2012).
23. M. Laplante, D.M. Sabatini, mTOR signaling in growth control and disease. Cell 149, 274-293 (2012).
24. P. P. Roux, D. Shahbazian, H. Vu, M. K. Holz, M. S. Cohen, J. Taunton, N. Sonenberg, J. Blenis, RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translation. J. Biol. Chem. 282, 14056-14064 (2007).
25. A. J. Folkes, K. Ahmadi, W. K. Alderton, S. Alix, S. J. Baker, G. Box, I. S. Chuckowree, P. A. Clarke, P. Depledge, S. A. Eccles, L. S. Friedman, A. Hayes, T. C. Hancox, A. Kugendradas, L. Lensun, P. Moore, A. G. Olivero, J. Pang, S. Patel, G. H. Pergl-Wilson, F. I. Raynaud, A. Robson, N. Saghir, L. Salphati, S. Sohal, M. H. Ultsch, M. Valenti, H. J. Wallweber, N. C. Wan, C. Wiesmann, P. Workman, A. Zhyvoloup, M. J. Zvelebil, S. J. Shuttleworth, The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl) -4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J. Med. Chem. 51, 5522-5532 (2008).
26. H. Zhang, G. Cicchetti, H. Onda, H. B. Koon, K. Asrican, N. Bajraszewski, F. Vazquez, C. L. Carpenter, D. J. Kwiatkowski, Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. J. Clin. Invest. 112, 1223-1233 (2003).
27. A. R. Tee, B. D. Manning, P. P. Roux, L. C. Cantley, J. Blenis, Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr. Biol. 13, 1259-1268 (2003).
28. E. A. Eisenhauer, P. Therasse, J. Bogaerts, L. H. Schwartz, D. Sargent, R. Ford, J. Dancey, S. Arbuck, S. Gwyther, M. Mooney, L. Rubinstein, L. Shankar, L. Dodd, R. Kaplan, D. Lacombe, J. Verweij, New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228-247 (2009).
29. R. Straussman, T. Morikawa, K. Shee, M. Barzily-Rokni, Z. R. Qian, J. Du, A. Davis, M. M. Mongare, J. Gould, D. T. Frederick, Z. A. Cooper, P. B. Chapman, D. B. Solit, A. Ribas, R. S. Lo, K. T. Flaherty, S. Ogino, J. A. Wargo, T. R. Golub, Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487, 500-504 (2012).
30. T. R. Wilson, J. Fridlyand, Y. Yan, E. Penuel, L. Burton, E. Chan, J. Peng, E. Lin, Y. Wang, J. Sosman, A. Ribas, J. Li, J. Moffat, D. P. Sutherlin, H. Koeppen, M. Merchant, R. Neve, J. Settleman, Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 487, 505-509 (2012).
31. F. Harbinski, V. J. Craig, S. Sanghavi, D. Jeffery, L. Liu, K. A. Sheppard, S. Wagner, C. Stamm, A. Buness, C. Chatenay-Rivauday, Y. Yao, F. He, C. X. Lu, V. Guagnano, T. Metz, P. M. Finan, F. Hofmann, W. R. Sellers, J. A. Porter, V. E. Myer, D. Graus-Porta, C. J. Wilson, A. Buckler, R. Tiedt, Rescue screens with secreted proteins reveal compensatory potential of receptor tyrosine kinases in driving cancer growth. Cancer Discov. 2, 948-959 (2012).
32. R. B. Corcoran, S. M. Rothenberg, A. N. Hata, A. C. Faber, A. Piris, R. M. Nazarian, R. D. Brown, J. T. Godfrey, D. Winokur, J. Walsh, M. Mino-Kenudson, S. Maheswaran, J. Settleman, J. A. Wargo, K. T. Flaherty, D. A. Haber, J. A. Engelman, TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma. Sci. Transl. Med. 5, 196ra98 (2013).
33. P. Liu, H. Cheng, S. Santiago, M. Raeder, F. Zhang, A. Isabella, J. Yang, D. J. Semaan, C. Chen, E. A. Fox, N. S. Gray, J. Monahan, R. Schlegel, R. Beroukhim, G. B. Mills, J. J. Zhao, Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms. Nat. Med. 17, 1116-1120 (2011).
34. M. K. Muellner, I. Z. Uras, B. V. Gapp, C. Kerzendorfer, M. Smida, H. Lechtermann, N. Craig-Mueller, J. Colinge, G. Duernberger, S. M. Nijman, A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer. Nat. Chem. Biol. 7, 787-793 (2011).
35. N. Ilic, T. Utermark, H. R. Widlund, T. M. Roberts, PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis. Proc. Natl. Acad. Sci. U.S.A. 108, E699-E708 (2011).
36. S. Institute, CONAN CGP copy number analysis; http://www.sanger.ac.uk/ research/areas/humangenetics/cnv/.
37. M. Wall, G. Poortinga, K. L. Stanley, R. K. Lindemann, M. Bots, C. J. Chan, M. J. Bywater, K. M. Kinross, M. V. Astle, K. Waldeck, K. M. Hannan, J. Shortt, M. J. Smyth, S. W. Lowe, R. D. Hannan, R. B. Pearson, R. W. Johnstone, G. A. McArthur, The mTORC1 inhibitor everolimus prevents and treats Em-Myc lymphoma by restoring oncogene-induced senescence. Cancer Discov. 3, 82-95 (2013).
38. S. M. Maira, F. Stauffer, J. Brueggen, P. Furet, C. Schnell, C. Fritsch, S. Brachmann, P. Chène, A. De Pover, K. Schoemaker, D. Fabbro, D. Gabriel, M. Simonen, L. Murphy, P. Finan, W. Sellers, C. García- Echeverría, Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol. Cancer Ther. 7, 1851-1863 (2008).
39. J. J. Wallin, K. A. Edgar, J. Guan, M. Berry, W. W. Prior, L. Lee, J. D. Lesnick, C. Lewis, J. Nonomiya, J. Pang, L. Salphati, A. G. Olivero, D. P. Sutherlin, C. O'Brien, J. M. Spoerke, S. Patel, L. Lensun, R. Kassees, L. Ross, M. R. Lackner, D. Sampath, M. Belvin, L. S. Friedman, GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway. Mol. Cancer Ther. 10, 2426-2436 (2011).
40. B. Markman, J. Tabernero, I. Krop, G. I. Shapiro, L. Siu, L. C. Chen, M. Mita, M. Melendez Cuero, S. Stutvoet, D. Birle, O. Anak, W. Hackl, J. Baselga, Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors. Ann. Oncol. 23, 2399-2408 (2012).
41. A. J. Wagner, J. C. Bendell, S. Dolly, J. A. Morgan, J. A. Ware, J. Fredrickson, K. E. Mazina, J. O. Lauchle, H. A. Burris, J. S. De Bono, A first-in-human phase I study to evaluate GDC-0980, an oral PI3K/mTOR inhibitor, administered QD in patients with advanced solid tumors. J. Clin. Oncol. 29, 3020 (2011).
42. H. Tanaka, M. Yoshida, H. Tanimura, T. Fujii, K. Sakata, Y. Tachibana, J. Ohwada, H. Ebiike, S. Kuramoto, K. Morita, Y. Yoshimura, T. Yamazaki, N. Ishii, O. Kondoh, Y. Aoki, The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations. Clin. Cancer Res. 17, 3272-3281 (2011).
43. T. Bachelot, C. Bourgier, C. Cropet, I. Ray-Coquard, J. M. Ferrero, G. Freyer, S. Abadie-Lacourtoisie, J. C. Eymard, M. Debled, D. Spaëth, E. Legouffe, D. Allouache, C. El Kouri, E. Pujade-Lauraine, Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: A GINECO study. J. Clin. Oncol. 30, 2718-2724 (2012).
44. J. Baselga, M. Campone, M. Piccart, H. A. Burris III, H. S. Rugo, T. Sahmoud, S. Noguchi, M. Gnant, K. I. Pritchard, F. Lebrun, J. T. Beck, Y. Ito, D. Yardley, I. Deleu, A. Perez, T. Bachelot, L. Vittori, Z. Xu, P. Mukhopadhyay, D. Lebwohl, G. N. Hortobagyi, Everolimus in postmenopausal hormonereceptor- positive advanced breast cancer. N. Engl. J. Med. 366, 520-529 (2012).
45. C. García-García, Y. H. Ibrahim, V. Serra, M. T. Calvo, M. Guzmán, J. Grueso, C. Aura, J. Pérez, K. Jessen, Y. Liu, C. Rommel, J. Tabernero, J. Baselga, M. Scaltriti, Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy. Clin. Cancer Res. 18, 2603-2612 (2012).
46. Y. H. Ibrahim, C. García-García, V. Serra, L. He, K. Torres-Lockhart, A. Prat, P. Anton, P. Cozar, M. Guzmán, J. Grueso, O. Rodríguez, M. T. Calvo, C. Aura, O. Díez, I. T. Rubio, J. Pérez, J. Rodón, J. Cortés, L. W. Ellisen, M. Scaltriti, J. Baselga, PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov. 2, 1036-1047 (2012).
47. M. Elkabets, A. M. Gifford, C. Scheel, B. Nilsson, F. Reinhardt, M. A. Bray, A. E. Carpenter, K. Jirström, K. Magnusson, B. L. Ebert, F. Pontén, R. A. Weinberg, S. S. McAllister, Human tumors instigate granulin-expressing hematopoietic cells that promote malignancy by activating stromal fibroblasts in mice. J. Clin. Invest. 121, 784-799 (2011).
48. Y. J. Choi, A. Di Nardo, I. Kramvis, L. Meikle, D. J. Kwiatkowski, M. Sahin, X. He, Tuberous sclerosis complex proteins control axon formation. Genes Dev. 22, 2485-2495 (2008).
49. J. Debnath, S. K. Muthuswamy, J. S. Brugge, Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 30, 256-268 (2003).
50. P. S. Kim, O. Von Ahsen, A. Schmitz, C. Schatz, K. Magonova, T. Lee, G. Harvie, R. Barham, G. Leesman, A. Kuller, F. Lin, H. Gong, T. Krahn, S. Singh, Pathway profiling of signal transduction proteins in paired tumor and adjacent normal tissues obtained from breast cancer patients. Cancer Res. 70 (2010).
51. M. Elkabets, S. Vora, D. Juric, N. Morse, M. Mino-Kenudson, T. Muranen, J. Tao, A. B. Campos, J. Rodon, Y. H. Ibrahim, V. Serra, V. Rodrik-Outmezguine, S. Hazra, S. Singh, P. Kim, C. Quadt, M. Liu, A. Huang, N. Rosen, J. A. Engelman, M. Scaltriti, J. Baselga, mTORC1 inhibition is required for sensitivity to PI3K p110a inhibitors in PIK3CA-mutant breast cancer. Sci. Transl. Med. 5, 196ra99 (2013).